S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
LON:AZN

AstraZeneca (AZN) Share Price, News & Analysis

GBX 9,983
-197.00 (-1.94%)
(As of 02/29/2024 ET)
Today's Range
9,982
£102.02
50-Day Range
9,501
£109.02
52-Week Range
9,461
£123.92
Volume
4.03 million shs
Average Volume
2.41 million shs
Market Capitalization
£154.74 billion
P/E Ratio
3,305.63
Dividend Yield
2.28%
Price Target
£117.13

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
17.3% Upside
£117.13 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.07mentions of AstraZeneca in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
£4.96 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars


AZN stock logo

About AstraZeneca Stock (LON:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

AZN Apr 2024 67.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AZN Mar 2024 57.000 call
AZN Mar 2024 68.000 put
AstraZeneca Stock (NASDAQ:AZN) Insider Trades
AstraZeneca Prices $5bln Four Tranche Notes Offering
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
AZN Oct 2024 62.500 put
AZN Feb 2024 69.000 call
Leerink Partners Reaffirms Their Buy Rating on AstraZeneca (AZN)
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/25 Dividend
2/22/2024
Today
2/29/2024
Dividend Payable
3/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
83,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
£117.13
High Stock Price Target
£135
Low Stock Price Target
GBX 9,500
Potential Upside/Downside
+15.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
£5.95 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£45.81 billion
Cash Flow
GBX 261.50 per share
Book Value
GBX 2,525 per share

Miscellaneous

Outstanding Shares
1,550,000,000
Free Float
N/A
Market Cap
£157.64 billion
Optionable
Not Optionable
Beta
0.19
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Pascal Soriot D.V.M. (Age 65)
    M.B.A., CEO & Executive Director
    Comp: $4.78M
  • Dr. Aradhana Sarin M.D. (Age 49)
    CFO & Executive Director
    Comp: $2.73M
  • Ms. Pam P. Cheng (Age 53)
    EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
  • Mr. Andrew P. Barnett
    Head of Investor Relations
  • Mr. Jeffrey Pott
    CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Nicolas Pangalos Ph.D. (Age 56)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Executive Vice-President of BioPharmaceuticals Business Unit
  • Dr. Susan Mary Galbraith M.D. (Age 58)
    Ph.D., Executive Vice President of Oncology Research & Development
  • Mr. Leon Wang
    Executive VP of International & China President














AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price target for 2024?

10 equities research analysts have issued 1-year price objectives for AstraZeneca's stock. Their AZN share price targets range from GBX 9,500 to £135. On average, they predict the company's share price to reach £117.13 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2024?

AstraZeneca's stock was trading at £106 on January 1st, 2024. Since then, AZN shares have decreased by 5.8% and is now trading at GBX 9,983.
View the best growth stocks for 2024 here
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Thursday, February 8th. Investors of record on Thursday, February 22nd will be given a dividend of GBX 156 per share on Monday, March 25th. This represents a dividend yield of 1.49%. The ex-dividend date is Thursday, February 22nd. This is a positive change from the stock's previous dividend of GBX 71.80. The official announcement can be viewed at this link.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 228 per share and currently has a dividend yield of 2.25%. The dividend payout ratio is 7,549.67%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AZN) was last updated on 2/29/2024 by MarketBeat.com Staff